Key clinical point: Secukinumab was effective in treating patients with psoriatic arthritis (PsA) in real-world clinical settings and generated high levels of satisfaction among physicians.
Major finding: At treatment initiation, 5.6%, 16.3%, and 8.7% of patients were categorized with mild disease, skin, and joint severity, which increased to 75.5%, 83.6%, and 77.6%, respectively, at the current consultation. Patients with Psoriasis Area Severity Index scores of less than 3 increased from 7.1% at treatment initiation to 64.3% at the current consultation. Physician satisfaction with secukinumab treatment was greater than 90% irrespective of disease severity at initiation and several other clinical parameters.
Study details: Findings are from a retrospective analysis of data collected for 572 patients with mild-to-severe PsA from 294 rheumatologists and 144 dermatologists. Included patients received either secukinumab 300 mg or 150 mg for at least 4 months .
Disclosures: This study was funded by Novartis. Dr. Conaghan and Dr. Kiltz declared receiving consultancy or speaker fees and/or research support from several sources including Novartis.
Source: Conaghan PG et al. Curr Med Res Opin. 2021 Jul 23. doi: 10.1080/03007995.2021.1954500 .